v3.26.1
Segment Information (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Reconciliation of Segment Loss Before Income Taxes and Total Consolidated Loss Before Income Taxes
The following table presents selected financial information with respect to the Company’s single operating segment for the three and six months ended June 30, 2026 and 2025 (in thousands):
Therapeutics Segment
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Product revenue, net$3,604 $— $3,604 $— 
Less:
Cost of goods sold93 — 93 — 
External research and development expenses - TV programs, including cost sharing40,419 37,594 78,883 84,052 
Other research and development expenses, including small molecule programs
16,494 24,847 40,048 54,347 
Personnel related research and development expenses
40,106 40,255 81,934 80,524 
Total research and development expenses97,019 102,696 200,865 218,923 
Personnel related selling, general and administrative expenses
22,921 20,115 45,485 38,853 
Other selling, general and administrative expenses
13,362 12,152 24,309 22,767 
Total selling, general and administrative expenses36,283 32,267 69,794 61,620 
Intangible asset amortization$750 $— $750 $— 
Segment operating expenses134,145 134,963 271,502 280,543 
Segment loss from operations(130,541)(134,963)(267,898)(280,543)
Segment interest and other income, net2,988 10,844 11,898 23,454 
Segment net loss
$(127,553)$(124,119)$(256,000)$(257,089)